BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8735830)

  • 1. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
    Sanderson HM; Heptinstall S; Vickers J; Lösche W
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):245-8. PubMed ID: 8735830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S; Nakahata N; Ohizumi Y
    Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.
    Hourani SM; Hall DA; Nieman CJ
    Br J Pharmacol; 1992 Feb; 105(2):453-7. PubMed ID: 1559134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors.
    Paul BZ; Jin J; Kunapuli SP
    J Biol Chem; 1999 Oct; 274(41):29108-14. PubMed ID: 10506165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
    Patscheke H; Stegmeier K
    Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood.
    Heptinstall S; May JA; Glenn JR; Sanderson HM; Dickinson JP; Wilcox RG
    Thromb Haemost; 1995 Nov; 74(5):1310-5. PubMed ID: 8607115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems.
    Takahara K; Murray R; FitzGerald GA; Fitzgerald DJ
    J Biol Chem; 1990 Apr; 265(12):6836-44. PubMed ID: 2139029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
    Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
    Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular ATP inhibits agonist-induced mobilization of internal calcium in human platelets.
    Soslau G; McKenzie RJ; Brodsky I; Devlin TM
    Biochim Biophys Acta; 1995 Jul; 1268(1):73-80. PubMed ID: 7626665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA.
    Krishnamurthi S; Joseph S; Kakkar VV
    Biochim Biophys Acta; 1987 Mar; 927(3):429-36. PubMed ID: 3101746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms.
    Praticò D; Smyth EM; Violi F; FitzGerald GA
    J Biol Chem; 1996 Jun; 271(25):14916-24. PubMed ID: 8663015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible dual physiological role of extracellular ATP in the modulation of platelet aggregation.
    Soslau G; Youngprapakorn D
    Biochim Biophys Acta; 1997 Feb; 1355(2):131-40. PubMed ID: 9042333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets.
    Yin K; Lai PS; Rodriguez A; Spur BW; Wong PY
    Prostaglandins; 1995 Sep; 50(3):169-78. PubMed ID: 8750213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregation of human and canine platelets: modulation by purine nucleotides.
    Soslau G; Arabe L; Parker J; Pelleg A
    Thromb Res; 1993 Oct; 72(2):127-37. PubMed ID: 8303650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.